Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sells $17,519.50 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 925 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $18.94, for a total value of $17,519.50. Following the completion of the transaction, the chief accounting officer now owns 54,002 shares in the company, valued at $1,022,797.88. This represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Sandra Calvin also recently made the following trade(s):

• On Thursday, December 26th, Sandra Calvin sold 15,000 shares of Travere Therapeutics stock. The shares were sold at an average price of $17.22, for a total value of $258,300.00.
• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.30, for a total value of $221,247.00.

Travere Therapeutics Stock Performance

Shares of TVTX opened at $20.31 on Friday. The stock has a 50-day simple moving average of $18.33 and a 200-day simple moving average of $14.91. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. Travere Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $21.56. The stock has a market capitalization of $1.59 billion, a PE ratio of -4.46 and a beta of 0.70.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.01. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The company had revenue of $62.90 million during the quarter, compared to the consensus estimate of $60.87 million. During the same quarter in the previous year, the firm earned ($1.17) earnings per share. The firm’s quarterly revenue was up 69.6% on a year-over-year basis. On average, analysts predict that Travere Therapeutics, Inc. will post -3.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Travere Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TVTX. abrdn plc acquired a new stake in Travere Therapeutics in the fourth quarter valued at $6,829,000. Jennison Associates LLC purchased a new position in shares of Travere Therapeutics in the 4th quarter valued at about $14,222,000. China Universal Asset Management Co. Ltd. raised its position in shares of Travere Therapeutics by 23.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,206 shares of the company’s stock worth $317,000 after acquiring an additional 3,494 shares in the last quarter. Baader Bank Aktiengesellschaft purchased a new stake in Travere Therapeutics during the fourth quarter worth approximately $192,000. Finally, R Squared Ltd acquired a new position in Travere Therapeutics in the fourth quarter valued at approximately $53,000.

Wall Street Analyst Weigh In

TVTX has been the subject of a number of recent analyst reports. Piper Sandler lifted their price target on shares of Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, November 14th. Wedbush lifted their target price on shares of Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a report on Wednesday, October 9th. Barclays upped their price target on Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Wells Fargo & Company raised Travere Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $9.00 to $27.00 in a research note on Monday, October 21st. Finally, Scotiabank increased their target price on Travere Therapeutics from $23.00 to $27.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.